Passive Transmission of COVID-19 Antibody From Mother to Infant

NCT ID: NCT05851911

Last Updated: 2023-07-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-01

Study Completion Date

2024-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

At present, there is no relevant research focusing on children's acquisition of novel coronavirus antibodies through maternal passive transmission. Therefore, this study assessed the changes of maternal passive transmission of COVID-19 antibodies by monitoring the specific antibodies of COVID-19 in young children; This will lay a foundation for further exploring the risk of COVID-19 infection in children and formulating immune prevention strategies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Passive Transmission of Maternal and Infant Antibodies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group 1

Mother not vaccinated with COVID-19 vaccine

sars-cov-2 vaccine or infection

Intervention Type BIOLOGICAL

Whether to vaccinate COVID-19 vaccine, or infect with sars-cov-2

Control group 2

The mother was vaccinated with COVID-19 vaccine before pregnancy, and was not infected during pregnancy

sars-cov-2 vaccine or infection

Intervention Type BIOLOGICAL

Whether to vaccinate COVID-19 vaccine, or infect with sars-cov-2

Control group 3

The mother was vaccinated with COVID-19 vaccine before pregnancy, and was infected during pregnancy

sars-cov-2 vaccine or infection

Intervention Type BIOLOGICAL

Whether to vaccinate COVID-19 vaccine, or infect with sars-cov-2

Experimental group

The mother was not vaccinated with COVID-19 vaccine before pregnancy, so she was infected during pregnancy

sars-cov-2 vaccine or infection

Intervention Type BIOLOGICAL

Whether to vaccinate COVID-19 vaccine, or infect with sars-cov-2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sars-cov-2 vaccine or infection

Whether to vaccinate COVID-19 vaccine, or infect with sars-cov-2

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Children aged 0-2;
2. No history of blood transfusion, chemotherapy, or related immunosuppressive therapy; No immune system related diseases;

Exclusion Criteria

Not willing to participate
Minimum Eligible Age

0 Months

Maximum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Children's Hospital of Chongqing Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

yuting yang

researcher

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Yuting Yang

Chongqing, Chongqing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yuting Yang, Ms

Role: CONTACT

18990304808

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yuting Yang

Role: primary

18990304808

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-380

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.